Literature DB >> 17039236

Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique.

B Cauwelier1, H Cavé, C Gervais, M Lessard, C Barin, C Perot, J Van den Akker, F Mugneret, C Charrin, M P Pagès, M-J Grégoire, P Jonveaux, M Lafage-Pochitaloff, M J Mozzicconacci, C Terré, I Luquet, P Cornillet-Lefebvre, B Laurence, G Plessis, C Lefebvre, D Leroux, H Antoine-Poirel, C Graux, L Mauvieux, P Heimann, C Chalas, E Clappier, B Verhasselt, Y Benoit, B D Moerloose, B Poppe, N Van Roy, K D Keersmaecker, J Cools, F Sigaux, J Soulier, A Hagemeijer, A D Paepe, N Dastugue, R Berger, F Speleman.   

Abstract

Recently, we and others described a new chromosomal rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) involving the T-cell receptor beta (TCRbeta) (7q34) and the HOXA gene locus (7p15) in 5% of T-cell acute lymphoblastic leukemia (T-ALL) patients leading to transcriptional activation of especially HOXA10. To further address the clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we studied 330 additional T-ALLs. This revealed TCRbeta-HOXA rearrangements in five additional patients, which brings the total to 14 cases in 424 patients (3.3%). Real-time quantitative PCR analysis for HOXA10 gene expression was performed in 170 T-ALL patients and detected HOXA10 overexpression in 25.2% of cases including all the cases with a TCRbeta-HOXA rearrangement (8.2%). In contrast, expression of the short HOXA10 transcript, HOXA10b, was almost exclusively found in the TCRbeta-HOXA rearranged cases, suggesting a specific role for the HOXA10b short transcript in TCRbeta-HOXA-mediated oncogenesis. Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRbeta-HOXA rearranged cases except for deletion 9p21 and NOTCH1 activating mutations, which were present in 64 and 67%, respectively. In conclusion, this study defines TCRbeta-HOXA rearranged T-ALLs as a distinct cytogenetic subgroup by clinical, immunophenotypical and molecular genetic characteristics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039236     DOI: 10.1038/sj.leu.2404410

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

2.  Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Authors:  Sarah H Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D Aplan
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

3.  The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report.

Authors:  Jay L Patel; Lynette M Smith; James Anderson; Minnie Abromowitch; Dario Campana; Jeffrey Jacobsen; Mark A Lones; Thomas G Gross; Mitchell S Cairo; Sherrie L Perkins
Journal:  Br J Haematol       Date:  2012-09-21       Impact factor: 6.998

4.  Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.

Authors:  Faisal M Alseraye; Zhuang Zuo; Carlos Bueso-Ramos; Sa Wang; L Jeffrey Medeiros; Gary Lu
Journal:  Int J Clin Exp Pathol       Date:  2011-04-25

5.  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Martine van Grotel; Joëlle Tchinda; Charles Lee; H Berna Beverloo; Peter J van der Spek; Andrew Stubbs; Jan Cools; Kyosuke Nagata; Maarten Fornerod; Jessica Buijs-Gladdines; Martin Horstmann; Elisabeth R van Wering; Jean Soulier; Rob Pieters; Jules P P Meijerink
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

6.  T-cell Acute Lymphoblastic Leukemia with del (7) (q11.2q22) and Aberrant Expression of Myeloid Markers.

Authors:  Ahmad Ahmadzadeh; Sajedeh Saedi; Kaveh Jaseb; Ali Amin Asnafi; Arash Alghasi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

7.  Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.

Authors:  Diogo F T Veiga; Mathieu Tremblay; Bastien Gerby; Sabine Herblot; André Haman; Patrick Gendron; Sébastien Lemieux; Juan Carlos Zúñiga-Pflücker; Josée Hébert; Joseph Paul Cohen; Trang Hoang
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

Review 8.  Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets.

Authors:  Eulàlia Genescà; Roberta la Starza
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.639

9.  A rare case of B cell lymphoblastic leukemia with inv(7)(p15q34) with review of literature.

Authors:  Bernhisel Andrew; Orazi Attilio; Guar Sumit; Tonk Vijay; Ghafouri Sayed Reshad; Padilla Osvaldo
Journal:  Leuk Res Rep       Date:  2021-06-01

10.  Increased levels of the long noncoding RNA, HOXA-AS3, promote proliferation of A549 cells.

Authors:  Hongyue Zhang; Ying Liu; Lixin Yan; Min Zhang; Xiufeng Yu; Wei Du; Siqi Wang; Qiaozhi Li; He Chen; Yafeng Zhang; Hanliang Sun; Zhidong Tang; Daling Zhu
Journal:  Cell Death Dis       Date:  2018-06-13       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.